In support of this concept, we and others have shown that genetic deletion or pharmacologic inhibition of ACE2 worsens experimental kidney disease including diabetic nephropathy and unilateral ureteral obstruction, while administration of recombinant ACE2 or over-expression of ACE2 improves kidney injury [18]–[23]. The gene discussed is ACE2; the disease is Ureteral obstruction.